SR-318

• UNSPSC Description:

  SR-318 is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC50 of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity[1].

• Target Antigen:

  p38 MAPK; TNF Receptor

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;MAPK/ERK Pathway

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/sr-318.html

• Smiles:

  O=C(C1=C(N)N(C2=CC=CC=C2)N=C1)NCC3=CC=C(C(NCCCC4CCCCC4)=O)C=C3

• Molecular Weight:

  459.58

• References & Citations:

  [1]Röhm S, et al. Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. J Med Chem. 2019 Dec 12;62(23):10757-10782.

• Shipping Conditions:

  Room Temperature

• CAS Number:

  2413286-32-3